ClinicalTrials.Veeva

Menu

Does Ultraviolet Irradiation Reduce Platelet Reactivity and Improve Coronary Microvascular Function in Man?

U

University of Edinburgh

Status

Completed

Conditions

Hypertension

Treatments

Radiation: UVA Radiation

Study type

Interventional

Funder types

Other

Identifiers

NCT01785511
UVA Study

Details and patient eligibility

About

Endothelium derived nitric oxide (NO) regulates vascular tone and blood pressure in man. NO also inhibits platelet aggregation and mediates a variety of beneficial anti-inflammatory and repair mechanisms. NO may also be a mediator in the release of the endogenous fibrinolytic factor, tissue-plasminogen activating factor (t-PA) from the endothelium.1 Via these actions it plays a very important role in protection of the vasculature from atherothrombosis and clinical sequelae such as myocardial infarction and stroke.

Visible and ultraviolet (UV) light relax vascular smooth muscles by producing NO in a phenomenon known as photorelaxation.2 The investigators have demonstrated significant stores of pre-formed, bound NO and other nitrosospecies in human skin, which are rapidly released upon exposure to UVA.3 The investigators have demonstrated recently that serum nitrite and nitroso-species are increased after standing in a UVA phototherapy cabinet and that local UVA exposure is associated with increased forearm arterial blood flow that is independent of skin temperature. The investigators have also demonstrated a fall in mean arterial blood pressure in subjects exposed UVA.

Cardiovascular morbidity and the prevalence of hypertension vary with latitude. The investigators hypothesise that some of this geographical variation may be explained by a diminished sunlight/UVA exposure with attendant negative effects upon NO bio-availability.4 To further examine the potential beneficial effects of UVA exposure we will examine the effects of whole-body UVA upon platelet activation and upon myocardial/coronary arterial flow reserve. The investigators will correlate these measures with systemic nitrate, nitrite and nitroso-species content in healthy volunteers.

HYPOTHESES

  1. UVA irradiation enhances coronary flow reserve in healthy volunteers.
  2. UVA irradiation suppresses platelet activation in healthy volunteers.
  3. UVA irradiation enhances the release of endogenous fibrinolytic factors in healthy volunteers.

Enrollment

12 patients

Sex

Male

Ages

18 to 45 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Healthy male volunteers aged between 18-45 years (inclusive).

Exclusion criteria

  • Inability to provide informed consent
  • Co-existent systemic disease (including any history of asthma, reactive airways disease or hypertension)
  • Contraindication to UVA treatment
  • Any history of cardiac conduction abnormality (including bundle branch block or atrial fibrillation)
  • Smoker
  • Current intake of aspirin, other non-steroid anti-inflammatory medications or any regular medication.
  • Recent infective/inflammatory condition
  • Echocardiographic evidence of left ventricular hypertrophy (left ventricular septal diameter >1.2 cm in diastole), systolic dysfunction or significant valvular stenosis or regurgitation.

Trial design

Primary purpose

Basic Science

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

None (Open label)

12 participants in 2 patient groups

Sham UVA
Sham Comparator group
Description:
sham exposure will be provided by covering the UVA lamps with space blanket.
Treatment:
Radiation: UVA Radiation
UVA Radiation
Experimental group
Description:
Patients will be exposed to UVA radiation for 20 minutes
Treatment:
Radiation: UVA Radiation

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems